Terns Pharmaceuticals, Inc. (TERN) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
TERN currently has 115M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 62.94% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 30, 2026 |
10-K filing | 115.4M shares outstanding |
120M | 0 |
| Aug 05, 2025 |
10-Q filing | 91.6M shares outstanding |
92M | 0 |
| May 08, 2025 |
S-3 filing: Terns Pharmaceuticals, Inc. is offering common stock, preferred stock, debt securities, depositary shares, subscription rights, warrants and units up to $300,000,000 in aggregate offering price. |
80M | 0 |
| May 08, 2025 |
10-Q filing | 91.5M shares outstanding |
91M | 0 |
| Mar 20, 2025 |
10-K filing | 79.5M shares outstanding |
80M | 0 |
| Nov 12, 2024 |
10-Q filing | 77.8M shares outstanding |
78M | 0 |
| Aug 05, 2024 |
10-Q filing | 74.5M shares outstanding |
74M | 0 |
| May 13, 2024 |
10-Q filing | 64.7M shares outstanding |
65M | 0 |
| Mar 14, 2024 |
10-K filing | 64.7M shares outstanding |
65M | 0 |
| Nov 14, 2023 |
10-Q filing | 61.8M shares outstanding |
62M | 0 |
| Aug 08, 2023 |
10-Q filing | 61.1M shares outstanding |
61M | 0 |
| May 15, 2023 |
10-Q filing | 56.7M shares outstanding |
57M | 0 |
| Mar 27, 2023 |
10-K filing | 56.7M shares outstanding |
57M | 0 |
| Feb 01, 2023 |
S-3 filing: Terns Pharmaceuticals, Inc. may offer and sell securities from time to time in one or more offerings of up to $400,000,000 in aggregate offering price. |
39M | 0 |
| Dec 23, 2022 |
8-K filing: Terns Pharmaceuticals, Inc. completed an underwritten public offering of 10,350,000 shares of common stock at $7.25 per share, with the underwriters exercising their option to purchase an additional 1,552,500 shares, resulting in net proceeds of approximately $80.8 million. ($80.8M proceeds) |
39M | 0 |
| Nov 09, 2022 |
10-Q filing | 38.5M shares outstanding |
39M | 0 |
| Aug 16, 2022 |
8-K filing: Terns Pharmaceuticals, Inc. completed an underwritten offering of 12,250,000 shares of common stock and pre-funded warrants to purchase 14,630,000 shares of common stock at a price of $2.42 and $2.4199 respectively, resulting in net proceeds of approximately $60.7 million. |
25M | 0 |
| Aug 08, 2022 |
10-Q filing | 25.4M shares outstanding |
25M | 80M |
| May 16, 2022 |
10-Q filing | 25.3M shares outstanding |
25M | 80M |
| Mar 08, 2022 |
S-3 filing: Terns Pharmaceuticals, Inc. files an S-3 registration statement to offer and sell up to $250,000,000 in the aggregate of common stock, preferred stock, and debt securities from time to time in one or more offerings. |
25M | 80M |
| Mar 07, 2022 |
10-K filing | 25.3M shares outstanding |
25M | 0 |
| Nov 15, 2021 |
10-Q filing | 25.3M shares outstanding |
25M | 0 |
| Aug 16, 2021 |
10-Q filing | 25.1M shares outstanding |
25M | 0 |
| May 14, 2021 |
10-Q filing | 25.1M shares outstanding |
25M | 0 |